SNY SAR445399 Halted in NCFB: Four Programs Cut in Two Weeks

Sanofi (SNY) has suspended a Phase 2 study of SAR445399 in non-cystic fibrosis bronchiectasis (NCFB), marking the fourth pipeline program cut or discontinued under new CEO Belén Garijo in under two weeks. The decision was disclosed August 5 and officially registered on ClinicalTrials.gov on July 29, the day before Sanofi’s Q2 earnings call.

The randomized, double-blind, placebo-controlled trial (NCT07547436) had only enrolled in April 2026 and was testing SAR445399 against placebo on mucus plug score reduction in adults with NCFB, a chronic lung disease affecting roughly 500,000 people in the United States. A Sanofi spokesperson told Fierce Biotech the pause was “for strategic business reasons” and not due to any safety concern.

SAR445399 is an anti-IL-1R3 monoclonal antibody that blocks signaling through the interleukin-1, interleukin-33, and interleukin-36 cytokine pathways. A separate Phase 2 study of the drug in hidradenitis suppurativa, an inflammatory skin condition, continues.

The suspension extends an aggressive portfolio purge that began with Sanofi’s decision to scrap amlitelimab in atopic dermatitis on July 24. During the Q2 earnings call, the company added two more pipeline terminations: itepekimab in COPD and balinatunfib in Crohn’s disease and ulcerative colitis. Itepekimab, partnered with Regeneron, had already failed the AERIFY-1 and AERIFY-2 Phase 3 trials in COPD last year. Balinatunfib, an oral TNF inhibitor developed with UCB, missed efficacy expectations in Phase 2 studies across psoriasis, Crohn’s, and ulcerative colitis.

The combined write-downs from these cuts exceeded €1 billion in Q2 impairment charges.

Garijo, who took over from Paul Hudson in February 2026, has characterized the moves as a “portfolio strategic assessment,” a line-by-line review of the late-stage pipeline. The pattern is clear: assets that lack compelling differentiation against existing therapies, including Sanofi’s own Dupixent (€5.2B quarterly sales), are being cleared out. Amlitelimab’s Phase 3 data, while statistically positive, did not show a meaningful improvement over Dupixent in eczema. Itepekimab had already missed in COPD. Balinatunfib could not match injectable biologics in inflammatory bowel disease.

For SAR445399 in NCFB, the competitive bar shifted in August 2025 when Insmed’s Brinsupri (brensocatib), a DPP1 inhibitor, became the first FDA-approved therapy for the indication. With Brinsupri already on the market, an early-stage anti-IL-1R3 antibody targeting mucus plugging faced a steeper commercial case.

What to watch next: Garijo said the portfolio review is “still ongoing,” meaning more cuts are possible. Sanofi’s Q2 earnings confirmed 2026 sales growth guidance of around 10%, but the near-term pipeline has thinned to a handful of late-stage assets led by Dupixent in COPD and tolebrutinib in multiple sclerosis. The stock closed at $43.46 on August 7, near the lower end of its 52-week range of $40 to $58, reflecting the market’s skepticism about near-term catalysts.

Source: Sanofi suspends chronic lung disease phase 2 study, Fierce Biotech SAR445399 NCFB Phase 2 on ClinicalTrials.gov (NCT07547436)

What It Means for the Trade

Four cuts in two weeks, €1 billion in impairments, and a stock near the low end of its range — the market has already rendered its verdict on Sanofi’s near-term pipeline, and this suspension is confirmation rather than news. The trade-relevant frame is that Garijo is running a controlled demolition: killing assets that cannot beat Dupixent or existing standards, taking the write-downs in a compressed window, and clearing the deck so that the remaining story — Dupixent in COPD, tolebrutinib in MS — gets the capital and the attention. That is the right way to run a pipeline purge, and it is also the way that produces a thin near-term catalyst calendar, which is exactly what a $43 stock near its lows reflects.

Mechanism and Market Context

IL-1R3 (also called IL-1 receptor accessory protein) is a shared signaling hub: blocking it dampens IL-1, IL-33, and IL-36 pathways at once — three cytokine axes relevant to inflammatory disease. That breadth is the mechanism’s promise and its problem: broad upstream blockade can look undifferentiated in any single indication where a specific pathway drug already exists. In NCFB, the trial targeted mucus plug score — a mechanistically plausible endpoint given IL-33’s role in mucus biology — but plausibility does not survive contact with a market that now has an approved therapy in Brinsupri and Insmed building the indication’s commercial infrastructure. The pattern across all four cuts — amlitelimab, itepekimab, balinatunfib, now SAR445399 — is consistent: no differentiation, no spend.

Risks and What Could Go Wrong

1. Cuts overshoot. A purge this fast can discard assets whose value was not yet legible; if the survivors then stumble, the pipeline has no bench left.
2. Dupixent COPD dependence. The entire post-purge thesis concentrates on one readout; a miss there leaves Sanofi with a great current franchise and a hollowed-out future.
3. Tolebrutinib risk. The MS program carries the BTK-class safety overhang that killed competitors’ programs; it is not a free option.
4. Talent and morale. Serial pipeline kills drain the development organization; execution quality on what remains is the quiet casualty of aggressive culls.

Net: a rational, painful cleanup. The stock’s skepticism is earned; the re-rating trade is Dupixent-COPD, not the cut list.